Biopartners has received marketing authorization for the EU from the European Commission for its biosimilar medicinal product Valtropin, a recombinant human growth hormone used for the treatment of human growth deficiency in children and Turner’s Syndrome. Biopartners, jointly with LG Life Sciences, has co-developed a number of biopharmaceutical products including Valtropin and a sustained release formulation of Valtropin. Biopartners in-licensed Valtropin from LG Life Sciences and has com...